Wilfredo Gonzalez, MD
Internal Medicine · Doral, FLNPI 1518074558
Payments from drug & device makers
Across 82 payments — averaging $67.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$4K
- Sanofi-aventis U.S. LLC$335
- Johnson & Johnson$192
- Amarin Pharma, Inc.$181
- Novo Nordisk$167
- Pfizer$93
- plus $538 from 12 others
What the payments were for
- Consulting fees$3,60065%
- Food & beverage$1,92335%
- Education$150%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 14 | $4,033 |
| Sanofi-aventis U.S. LLC | 10 | $335 |
| Johnson & Johnson | 11 | $192 |
| Amarin Pharma, Inc. | 4 | $181 |
| Novo Nordisk | 9 | $167 |
| Pfizer | 5 | $93 |
| AstraZeneca | 5 | $83 |
| Biogen | 3 | $71 |
| Zyla Life Sciences, Inc. | 4 | $64 |
| Merck | 3 | $59 |
| Arbor Pharmaceuticals, Inc. | 3 | $47 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $44 |
| Kowa Pharmaceuticals America, Inc. | 2 | $38 |
| Lilly USA, LLC | 2 | $32 |
| Boehringer Ingelheim | 2 | $32 |
| TG Therapeutics, Inc. | 1 | $26 |
| AbbVie | 1 | $23 |
| GSK | 1 | $20 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,538 in reported general payments places this provider in the 85th percentile of 8,530 internal medicine providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 22 | $34,975 |
| MounjaroTirzepatide | 30 | $34,213 |
| TradjentaLinagliptin | 16 | $24,963 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 17 | $23,057 |
| JanuviaSitagliptin Phosphate | 17 | $22,924 |
| OzempicSemaglutide | 19 | $17,114 |
| EliquisApixaban | 17 | $16,323 |
| VascepaIcosapent Ethyl | 21 | $12,409 |
| XareltoRivaroxaban | 13 | $9,205 |
| Rosuvastatin Calcium | 242 | $3,232 |
| Atorvastatin Calcium | 205 | $1,560 |
| Levothyroxine Sodium | 159 | $1,371 |
| Diclofenac Sodium | 37 | $1,046 |
| Famotidine | 43 | $994 |
| Losartan Potassium | 132 | $837 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Tradjenta, Synjardy Xr | $32 | $82,99455 claims |
| Lilly USA, LLCMounjaro | $32 | $34,21330 claims |
| MerckJanuvia | $59 | $22,92417 claims |
| Novo NordiskOzempic | $167 | $17,11419 claims |
| PfizerEliquis | $93 | $16,32317 claims |
| Johnson & JohnsonXarelto | $192 | $9,20513 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 8,530 internal medicine providers in Florida.
Other internal medicine in Doral
- Luis MartinezDoral$13.8M
- Jorge VenereoDoral$4.4M
- Yaneicy Gonzalez RojasCoral Gables$93.5M
- Juan Carlos RondonHollywood$66.8M
- Jaynier MoyaPembroke Pines$45.4M
- Mark KutnerMiami$35.7M
- Gilberto JimenezHialeah$35.6M
- Mira BaronWest Palm Beach$29.6M
- William SanchezHialeah$28.9M
- Nelia Sanchez-CrespoHollywood$28.8M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.